- Home
- AMAL vs CDNA Comparison
AMAL vs CDNA Comparison
Compare AMAL & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AMAL | CDNA |
|---|---|---|
| Founded | 1923 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 966.6M | 712.2M |
| IPO Year | 2018 | 2014 |
Fundamental Metrics
Financial Performance| Metric | AMAL | CDNA |
|---|---|---|
| Price | $32.31 | $19.92 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $33.50 | $26.00 |
| AVG Volume (30 Days) | 185.6K | ★ 816.3K |
| Earning Date | 01-22-2026 | 11-04-2025 |
| Dividend Yield | ★ 1.75% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.32 | 1.22 |
| Revenue | $306,936,000.00 | ★ $357,998,000.00 |
| Revenue This Year | $10.09 | $14.11 |
| Revenue Next Year | $8.37 | $12.00 |
| P/E Ratio | ★ $9.64 | $16.92 |
| Revenue Growth | 1.29 | ★ 14.46 |
| 52 Week Low | $25.03 | $10.96 |
| 52 Week High | $37.26 | $25.95 |
Technical Indicators
Market Signals| Indicator | AMAL | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 71.95 | 66.40 |
| Support Level | $31.81 | $18.36 |
| Resistance Level | $32.48 | $19.95 |
| Average True Range (ATR) | 0.76 | 0.87 |
| MACD | 0.20 | 0.16 |
| Stochastic Oscillator | 93.95 | 75.85 |
Price Performance
Historical ComparisonAbout AMAL Amalgamated Financial Corp. (DE)
Amalgamated Financial Corp is a bank holding company. It is a full-service commercial bank and a chartered trust company. It provides commercial banking and trust services nationally and offers various products and services to commercial and retail customers. It offers a complete suite of commercial and retail banking, investment management and trust and custody services.
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.